This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Bears are Losing Control Over Molina (MOH), Here's Why It's a 'Buy' Now
by Zacks Equity Research
Molina (MOH) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Should Value Investors Buy Molina Healthcare (MOH) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks.com featured highlights Sterling Infrastructure, BJ's Wholesale, Molina Healthcare and Halozyme
by Zacks Equity Research
Sterling, BJ's, Molina, and Halozyme stand tall with robust earnings growth and high interest coverage in June picks.
4 Stocks With Strong Interest Coverage Ratios to Buy in June 2025
by Sumit Singh
STRL, BJ, MOH, and HALO shine with strong interest coverage ratios, signaling solid fundamentals for June 2025.
Molina (MOH) Down 1.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Molina (MOH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights UnitedHealth, Centene and Molina Healthcare
by Zacks Equity Research
UnitedHealth, Centene and Molina Healthcare are part of the Zacks top Analyst Blog.
This Is Why UnitedHealth Stock Bounced Back, But Is Better to Avoid
by Tirthankar Chakraborty
Does UnitedHealth's Insiders scooping up shares of UNH justify a buy decision today? Let's explore -
Zacks.com featured highlights Sterling Infrastructure, AXIS Capital, Molina Healthcare and Halozyme
by Zacks Equity Research
Sterling Infrastructure, AXIS Capital, Molina Healthcare and Halozyme have been highlighted in this Screen of The Week article.
4 Stocks With Impressive Interest Coverage Ratio to Buy Now
by Sumit Singh
STRL, AXS, MOH & HALO's impressive interest coverage ratios highlight that these companies can withstand financial hardships.
Are Investors Undervaluing Molina Healthcare (MOH) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Centene Q1 Earnings Beat Estimates on Marketplace Business Strength
by Zacks Equity Research
CNC's Q1 results benefit from improved premiums as a result of a strong PDP business, partly offset by elevated operating costs. It currently expects 2025 premium and service revenues within $164-$166 billion.
Molina Healthcare Q1 Earnings Beat Estimates on Growing Premiums
by Zacks Equity Research
MOH continues to expect 2025 premium revenues to be around $42 billion.
Here's What Key Metrics Tell Us About Molina (MOH) Q1 Earnings
by Zacks Equity Research
Although the revenue and EPS for Molina (MOH) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Molina (MOH) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Molina (MOH) delivered earnings and revenue surprises of 3.75% and 0.24%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Molina Healthcare to Report Q1 Earnings: Key Estimates to Watch
by Zacks Equity Research
MOH's first-quarter earnings are likely to have benefited from growing premiums, partially offset by higher expenses.
Insights Into Molina (MOH) Q1: Wall Street Projections for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Molina (MOH) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Centene (CNC) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Centene (CNC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Molina (MOH) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Molina (MOH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How Should You Play UnitedHealth Stock Going Into Q1 Earnings?
by Kaibalya Pravo Dey
UNH's first-quarter earnings are likely to have benefited from growing premiums and service revenues.
Is iShares MSCI USA Equal Weighted ETF (EUSA) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for EUSA
Humana Gains on Strong Membership Base and Sound Cash Reserves
by Zacks Equity Research
HUM benefits from a cost-effective health plan suite, continued expansion endeavors and a strong 2025 business outlook.
Molina Healthcare Expands Presence With Illinois D-SNP Contract Win
by Zacks Equity Research
MOH secures a key Illinois contract, strengthening its foothold in the dual-eligible market.
Molina (MOH) Up 13.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Molina (MOH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Molina Healthcare Q4 Earnings Miss Estimates on Growing Medical Costs
by Zacks Equity Research
MOH expects total membership to be at 5.9 million by 2025-end.
Compared to Estimates, Molina (MOH) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Molina (MOH) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.